Where does Momenta Pharmaceuticals, Inc. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Momenta Pharmaceuticals, Inc. ranks #5,301 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Momenta Pharmaceuticals, Inc. hold?

Momenta Pharmaceuticals, Inc. holds 65 US utility patents granted between 2015 and 2025, spanning 23 technology areas.

What is Momenta Pharmaceuticals, Inc.'s Innovation Score?

Momenta Pharmaceuticals, Inc. has an Innovation Score of 50.6 out of 100 (top 13% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Momenta Pharmaceuticals, Inc. focus on?

Momenta Pharmaceuticals, Inc.'s top technology area is C07K (Peptides) with 50 patents, ranking #179 of 3,615 assignees active in that subclass. Grants appear in 23 CPC subclasses total.

Is Momenta Pharmaceuticals, Inc.'s patent grant rate increasing or decreasing?

Momenta Pharmaceuticals, Inc.'s recent grant velocity is -64% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Momenta Pharmaceuticals, Inc.'s patents?

Momenta Pharmaceuticals, Inc.'s patents average 19.8 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Momenta Pharmaceuticals, Inc. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView US Corporation

Momenta Pharmaceuticals, Inc.

USPTO PatentsView assignee record - 65 granted patents across 23 technology areas, recorded in grant years 2015–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C07K (Peptides).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Momenta ranks #5,301 of 49,997 tracked US assignees by granted-patent volume, with 65 patents across 23 technology areas.

#5,301
of 49,997 US assignees by volume: Top 13%
by Innovation Score (50.6/100): 19.8
avg claims per patent: -64%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R5301 · US Corporation #5,301 · 65 grants

GRANTS-SMALL · UPPER-Q · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL

GRANTS-SMALL 65 grants
UPPER-Q #5,301/49,997
PHOTO-FINISH Kinaxis
CPC-FOCUS C07K · 23 areas
INNOV-PAR 50.6/100
CLAIMS-RICH 19.8 claims/avg
TYPE-USCORP US Corporation
VEL-DROP -64% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Kinaxis Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

Qualcomm Incorporated · highest

85
ENDRESS+HAUSER +KG · near

51
King Slide Technology · near

51
Momenta Pharmaceutic… · this assignee

51
Niigata University · near

51
Societe BIC · near

51
3D Lighting… · lowest

7

What this shows Momenta's Innovation Score is 50.6/100 (top 13% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Where Momenta's grants concentrate

Momenta Pharmaceuticals, Inc. is a focused PatentsView assignee: 23 CPC subclasses with 76.9% of grants classified under C07K (Peptides). Peak complete grant year is 2015 (13 grants) versus a trough of 2 in 2022. By volume, Momenta sits between Kinaxis Inc. and NovAtel Inc..

Momenta's three-year grant acceleration

Momenta Pharmaceuticals, Inc. shows 12 grants in 2022–2024 against only 11 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Kinaxis

65
Konkuk University…

65
Kunming Universit…

65
Liebherr-verzahnt…

65
Moneygram Interna…

65
Neonode

65
Nielsen Consumer

65
Novatel

65
Momenta Pharmaceu… ◀

65

What this shows Momenta holds 65 patents at rank #5,300, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Momenta

By rank, the assignees closest to #5,300 in granted patent volume.

Leaders in C07K (Peptides)

Other assignees with the most granted patents in Momenta's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Momenta, neither rank-band nor same-CPC leaders (those blocks stay above). In C07K (Peptides), Momenta ranks #179 of 3,615 assignees by patent count in that subclass.

Similar innovation score

Nearest assignees by Innovation Score (51 here).

ENDRESS+HAUSER GMBH+CO.KG 51 Societe BIC 51 Niigata University 51 King Slide Technology Co., Ltd. 51

Similar claim depth

Nearest assignees by average claims per patent (19.8 here).

Calix, Inc. 19.8 avg Perceive Corporation 19.8 avg Igus GMBH 19.8 avg NuCurrent, Inc. 19.8 avg

Momenta's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

51 Top 13% higher than 87% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Momenta Pharmaceuticals, Inc. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	13	20.0%
2016	8	12.3%
2017	6	9.2%
2018	10	15.4%
2019	7	10.8%
2020	4	6.2%
2022	2	3.1%
2023	7	10.8%
2024	3	4.6%
2025partial year	5	7.7%

Which technologies does Momenta Pharmaceuticals, Inc. patent most?

C07K - Peptides 50

G01N - Investigating OR Analysing Materials BY Determining Their Chemical OR Physical Properties 31

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 26

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 25

C12P - Fermentation OR Enzyme-using Processes TO Synthesise A Desired Chemical Compound OR Composition OR TO Separate Optical Isomers From A Racemic Mixture 19

C12Q - Measuring OR Testing Processes Involving Enzymes, Nucleic Acids OR Microorganisms ; Compositions OR Test Papers THEREFOR; Processes OF Preparing Such COMPOSITIONS; Condition-responsive Control IN Microbiological OR Enzymological Processes 8

C08B - POLYSACCHARIDES; Derivatives Thereof 7

C12Y - Enzymes 6

C08G - Macromolecular Compounds Obtained Otherwise Than BY Reactions Only Involving Unsaturated Carbon-to-carbon Bonds 6

C12N - Microorganisms OR ENZYMES; Compositions THEREOF; Propagating, Preserving, OR Maintaining MICROORGANISMS; Mutation OR Genetic ENGINEERING; Culture Media 6

Y02A - Technologies FOR Adaptation TO Climate Change 5

Y10T - Technical Subjects Covered BY Former US Classification 5

B01D - Separation 4

H01J - Electric Discharge Tubes OR Discharge Lamps 2

C08L - Compositions OF Macromolecular Compounds 2

Top 15 of 23 technology areas

Where it ranks

Overall rank by patents

#5,301

of 49,997 tracked assignees

Innovation Score

50.6 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

What to do with this data

Momenta Pharmaceuticals, Inc.'s patent record in context - here's where to go next.

Momenta Pharmaceuticals, Inc.'s lead technology class is C07K (Peptides), 76.9% of its portfolio - see every assignee active in that class. Explore C07K
Ranked #5,301 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Momenta Pharmaceuticals, Inc. against Kinaxis Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 50.6/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.